Verve Therapeutics Inc
NASDAQ:VERV

Watchlist Manager
Verve Therapeutics Inc Logo
Verve Therapeutics Inc
NASDAQ:VERV
Watchlist
Price: 4.45 USD -3.26% Market Closed
Market Cap: 396.7m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+34%
Revenue
Forecast
0%
Operating Income
Forecast
+16%
Net Income
Forecast
+57%

Wall Street
Price Targets

VERV Price Targets Summary
Verve Therapeutics Inc

Wall Street analysts forecast VERV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VERV is 25.67 USD with a low forecast of 15.15 USD and a high forecast of 40.95 USD.

VERV Lowest Forecast
Wall Street Target
15.15 USD
240% Upside
VERV Average Forecast
Wall Street Target
25.67 USD
477% Upside
VERV Highest Forecast
Wall Street Target
40.95 USD
820% Upside
Lowest
Price Target
15.15 USD
240% Upside
Average
Price Target
25.67 USD
477% Upside
Highest
Price Target
40.95 USD
820% Upside
Verve Therapeutics Inc Competitors:
Price Targets
FYB
Formycon AG
141% Upside
STOK
Stoke Therapeutics Inc
155% Upside
AMGN
Amgen Inc
11% Upside
N
688105
Nanjing Vazyme Biotech Co Ltd
15% Upside
FYB
Formycon AG
141% Upside
STOK
Stoke Therapeutics Inc
155% Upside
AMGN
Amgen Inc
11% Upside
N
688105
Nanjing Vazyme Biotech Co Ltd
15% Upside
6855
Ascentage Pharma Group International
9% Upside
BNTX
BioNTech SE
44% Upside
BSLN
Basilea Pharmaceutica AG
100% Upside
MDGL
Madrigal Pharmaceuticals Inc
56% Upside

Revenue
Forecast

Revenue Estimate
Verve Therapeutics Inc

The compound annual growth rate of Verve Therapeutics Inc's revenue for the next 3 years is -24%.

N/A
Past Growth
-24%
Estimated Growth
Estimates Accuracy
51%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Verve Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Verve Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
What are analyst estimates?

See Also

Summary
VERV intrinsic value, competitors valuation, and company profile.
DCF Valuation
VERV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VERV stock valuation using valuation multiples.
Wall Street Estimates
VERV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VERV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VERV's stock price target?
Price Target
25.67 USD

According to Wall Street analysts, the average 1-year price target for VERV is 25.67 USD with a low forecast of 15.15 USD and a high forecast of 40.95 USD.

What is Verve Therapeutics Inc's Revenue forecast?
Projected CAGR
-24%

The compound annual growth rate of Verve Therapeutics Inc's revenue for the next 3 years is -24%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.